<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/669DFE5B-3E12-4E66-A6D0-388EF871D71B"><gtr:id>669DFE5B-3E12-4E66-A6D0-388EF871D71B</gtr:id><gtr:firstName>Cliff</gtr:firstName><gtr:surname>Elcombe</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/D9A82478-791F-40A9-81F4-3BC23215046B"><gtr:id>D9A82478-791F-40A9-81F4-3BC23215046B</gtr:id><gtr:firstName>B</gtr:firstName><gtr:surname>Burchell</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/12F12C0D-9536-40D7-AFB8-5B21203EFF9A"><gtr:id>12F12C0D-9536-40D7-AFB8-5B21203EFF9A</gtr:id><gtr:firstName>Sally</gtr:firstName><gtr:surname>Ibbotson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/FA046475-E739-4250-A317-8AEB60C0F68A"><gtr:id>FA046475-E739-4250-A317-8AEB60C0F68A</gtr:id><gtr:firstName>Ian</gtr:firstName><gtr:otherNames>C</gtr:otherNames><gtr:surname>Reid</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/EF0FBC1A-8437-4764-BA1D-5B30F46E1839"><gtr:id>EF0FBC1A-8437-4764-BA1D-5B30F46E1839</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:surname>Coughtrie</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/B6C852E6-0C7A-4BE3-BDF8-B6D61854F0A8"><gtr:id>B6C852E6-0C7A-4BE3-BDF8-B6D61854F0A8</gtr:id><gtr:firstName>John</gtr:firstName><gtr:otherNames>Duncan</gtr:otherNames><gtr:surname>Hayes</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0000281"><gtr:id>A35C8C83-54F3-4E3C-BBF8-474C08698122</gtr:id><gtr:title>The Dundee Molecular Pharmacology Cooperative Group</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0000281</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2006-06-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2001-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>505353</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Patient groups - Ninewells Hospital</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>CE86E155-9D00-4D13-9FBC-32104702B506</gtr:id><gtr:impact>Firstly, members of the co-operative included clinically active academics who by nature of their work meet the general public on a daily basis. Secondly, blood samples were collected from volunteers from the general public who would have to be told of the purpose of the studies to gain consent. Thirdly, the majority of the work of the CooP group finished before Jan 2006.

The research of this CooP group predated the general acceptance that personalized medicine is a desirable long term objective of the NHS.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK Project grant C4909/A9990</gtr:description><gtr:end>2011-04-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:id>BDB72CA2-AEFD-49A0-91C6-C0068D390741</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>158000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>AICR Project grant 07-0074</gtr:description><gtr:end>2010-03-02</gtr:end><gtr:fundingOrg>Association for International Cancer Research (AICR)</gtr:fundingOrg><gtr:fundingRef>07-0074</gtr:fundingRef><gtr:id>D05E0F17-CC1E-4216-986E-D7D932A91B02</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>156000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>AICR Project grant 06-015</gtr:description><gtr:end>2009-03-02</gtr:end><gtr:fundingOrg>Association for International Cancer Research (AICR)</gtr:fundingOrg><gtr:fundingRef>06-015</gtr:fundingRef><gtr:id>B326CB0A-22E2-4779-8D4A-B33474344FD3</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>240000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK Project grant C4909/A7161</gtr:description><gtr:end>2011-10-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:fundingRef>C4909/A7161</gtr:fundingRef><gtr:id>418FDD09-F3B9-4AEA-99C9-6F02D3E2B24E</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Personalized medicine - Ninewells Hospital</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>D4123263-9447-4E44-90FC-B5718D0B3EEB</gtr:id><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cancer chemoprevention - Dundee</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>3B8E18FC-B5A3-49BA-9C06-7191DA3B01DC</gtr:id><gtr:type>Citation in clinical reviews</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A large number of assays were developed to allow measurement of mRNA levels of genes regulated by Nrf2. Also, antibodies were raised against Nrf2 target genes, and Nrf2-/- MEF cell lines were generated.</gtr:description><gtr:id>EC5444DF-ED47-4D43-B648-3CA1738B7980</gtr:id><gtr:impact>We have been giving out reagents to researchers in the UK, Europe and USA relevant to Nrf2 since 2003.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Cancer chemoprevention - Dundee</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>DNA samples linked to patients</gtr:description><gtr:id>6AF9D413-1450-43CE-8A07-35B7622BCB79</gtr:id><gtr:impact>Substantial advances have been made in linking genetic variation to susceptibility to disease. However, such advances usually require very large patient groups to be collected and analyzed for polymorphisms, and this takes a long time. Members of the CooP group continue to be engaged in such activities.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Clinical materials - Ninewells hospital</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have Nrf2-/-, Keap1-floxed and Nrf1-floxed mouse lines.</gtr:description><gtr:id>DE295C71-FAD1-4F1C-8C68-54A241FBA8B1</gtr:id><gtr:impact>At least 50 publications have arisen from the transgenic mice mentioned above.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Transgenic mouse lines</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6B1EBC8C-6477-4FBB-BDC2-710706AFBC9C"><gtr:id>6B1EBC8C-6477-4FBB-BDC2-710706AFBC9C</gtr:id><gtr:title>Regulation of cutaneous drug-metabolizing enzymes and cytoprotective gene expression by topical drugs in human skin in vivo.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/adac6518578f2021c5823016d77e9f57"><gtr:id>adac6518578f2021c5823016d77e9f57</gtr:id><gtr:otherNames>Smith G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/436A0683-7366-4EAF-B784-17A7D380B4A9"><gtr:id>436A0683-7366-4EAF-B784-17A7D380B4A9</gtr:id><gtr:title>Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy.</gtr:title><gtr:parentPublicationTitle>The pharmacogenomics journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f672b4ea95f9e08b19a33c6ac401854f"><gtr:id>f672b4ea95f9e08b19a33c6ac401854f</gtr:id><gtr:otherNames>Wilkie MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1470-269X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B778FD65-66EB-4C66-B6F8-9BC4F1288E52"><gtr:id>B778FD65-66EB-4C66-B6F8-9BC4F1288E52</gtr:id><gtr:title>Cytochrome P450 CYP1B1 interacts with 8-methoxypsoralen (8-MOP) and influences psoralen-ultraviolet A (PUVA) sensitivity.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/30f7555797c144666980e61fdbe64667"><gtr:id>30f7555797c144666980e61fdbe64667</gtr:id><gtr:otherNames>Deeni YY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FE8EEB97-61A2-4055-97B4-A194A3BAAB76"><gtr:id>FE8EEB97-61A2-4055-97B4-A194A3BAAB76</gtr:id><gtr:title>Quantitative evaluation of the expression and activity of five major sulfotransferases (SULTs) in human tissues: the SULT &amp;quot;pie&amp;quot;.</gtr:title><gtr:parentPublicationTitle>Drug metabolism and disposition: the biological fate of chemicals</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fbf436d92c8ede69596df95397ebed4d"><gtr:id>fbf436d92c8ede69596df95397ebed4d</gtr:id><gtr:otherNames>Riches Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0090-9556</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E31AEE32-2F87-4E0C-ADAE-C3FFCE19B04D"><gtr:id>E31AEE32-2F87-4E0C-ADAE-C3FFCE19B04D</gtr:id><gtr:title>Melanocortin 1 receptor (MC1R) genotype influences erythemal sensitivity to psoralen-ultraviolet A photochemotherapy.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/adac6518578f2021c5823016d77e9f57"><gtr:id>adac6518578f2021c5823016d77e9f57</gtr:id><gtr:otherNames>Smith G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C1694D72-034F-4436-9553-063032CA43B9"><gtr:id>C1694D72-034F-4436-9553-063032CA43B9</gtr:id><gtr:title>Can dietary furanocoumarin ingestion enhance the erythemal response during high-dose UVA1 therapy?</gtr:title><gtr:parentPublicationTitle>Journal of the American Academy of Dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3be0ed899c18dbb6fe01c04e3bb2b513"><gtr:id>3be0ed899c18dbb6fe01c04e3bb2b513</gtr:id><gtr:otherNames>Beattie PE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0190-9622</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0000281</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>